1-methoxy-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenequinone | 60314-06-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: 1-methoxy-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenequinone
• 英文别名: 6,11-Dihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
• CAS: 60314-06-9
• 化学式: C₁₉H₁₆O₅
• 分子量: 324.333
• InChiKey: DRMRBUBTZRGJST-UHFFFAOYSA-N

物化性质

• 沸点：
  603.5±55.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-羟基-7-甲氧基-3H-2-苯并呋喃-1-酮 在 三氯化硼 、 dimsyl lithium 、 二甲基亚砜 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-methoxy-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenequinone
  参考文献：
  名称：

  Annelation reactions of quinone monoketals. Studies directed at an efficient synthesis of anthracyclinones

  摘要：

  DOI：

  10.1021/jo00176a020

文献信息

• [EN] PLATINUM-CONTAINING COMPOUNDS, AND RELATED COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS CONTENANT DU PLATINE, COMPOSITIONS ASSOCIÉES ET LEURS UTILISATIONS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2020214436A1

  公开（公告）日：2020-10-22

  Platinum-containing compounds are generally described. Inventive compositions and uses thereof are also described.

  含铂化合物通常被描述。创新的组成和用途也被描述。
• Synthesis, EPR, ENDOR and TRIPLE resonance investigations of anthracycline-related semiquinones
  作者：Hartmut B. Stegmann、Thomas Jülich、Ulrike Höfler、Paul Schuler、Wolfhard Koch、Karsten Krohn、Astrid Eickhoff

  DOI：10.1002/mrc.1260310510

  日期：1993.5

  substituted anthraquinones related to anthracyclines is described. One‐electron reduction of these compounds yields the corresponding semiquinones, which were characterized by EPR, ENDOR and TRIPLE resonance spectroscopy. The data indicate a rapid conformational interconversion of the cyclohexene moiety (ring A in the anthracyclines). The low‐temperature structures could be assigned to half‐chair conformers

  描述了与蒽环类相关的五种取代蒽醌的合成。这些化合物的单电子还原产生相应的半醌，其特征在于 EPR、ENDOR 和三重共振光谱。数据表明环己烯部分（蒽环类中的环 A）的快速构象相互转换。低温结构可以分配给半椅式构象异构体，其分裂常数和扭转角通过简单的计算得到。与已发表的结果相反，在 4 位引入取代基，扰乱了蒽醌的对称性，导致自旋密度分布发生显着变化。介绍了已知蒽醌自由基的重新解释和分配。
• RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY
  申请人：Cottarel Guillaume

  公开号：US20110015137A1

  公开（公告）日：2011-01-20

  The present invention provides RecA inhibitors, compositions containing them, systems for identifying or characterizing them, and methods of using them.
• CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
  申请人：Knoller Helmut

  公开号：US20130178437A1

  公开（公告）日：2013-07-11

  The present invention relates to hydroxyalkyl starch (HAS) conjugates and to a method for preparing the hydroxyalkyl starch (HAS) conjugates, the hydroxyalkyl starch (HAS) conjugates comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according the following formula HAS′(-M) n wherein M is a residue of a cytotoxic agent, the cytotoxic agent comprising a carbonyl group, HAS′ is a residue of the hydroxyalkyl starch derivative comprising at least one functional group X, n is greater than or equal to 1, and wherein the cytotoxic agent is linked via the carbonyl function present in the cytotoxic agent to the functional group X comprised in the hydroxyalkyl starch derivative, wherein the linkage via the carbonyl function is a cleavable linkage, which is capable of being cleaved in vivo so as to release the cytotoxic agent.
• [EN] DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES<br/>[FR] COMPOSÉS DÉGRADABLES ET LEURS PROCÉDÉS D'UTILISATION, IMPLIQUANT EN PARTICULIER UNE RÉPARTITION DES PARTICULES DANS DES MATRICES NON MOUILLANTES
  申请人：UNIV NORTH CAROLINA

  公开号：WO2009132265A2

  公开（公告）日：2009-10-29

  The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile -Si-A-C- groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C=O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.